OTC: DOGP
Dogecoin Cash, Inc.CIK 0001360442 · SIC 7200 · Personal Services
Dogecoin Cash, Inc. (the “Company”), formerly Cannabis Sativa, Inc. and previously Ultra Sun Corporation, was incorporated under the laws of the State of Nevada in November 2004. About this business →
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (COTY 10-K) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade DOGP commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 19, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statements of Operations (Unaudited)
| Description | Q2 ended Jun 30, 2026 | Q2 ended Jun 30, 2025 |
|---|---|---|
| Revenue: | ||
| Total revenue / net sales | 166,511 | 192,464 |
| Cost of revenue / cost of sales | 61,951 | 70,988 |
| Gross profit | 104,560 | 121,476 |
| Operating expenses: | ||
| Demand creation / marketing | 2,896 | 638.00 |
| Operating overhead | 108,341 | 186,873 |
| Depreciation and amortization | 279.00 | 302.00 |
| Total operating expenses | 217,515 | 304,892 |
| Operating income | (112,955) | (183,416) |
| Interest expense | 13,951 | 11,918 |
| Other income/(expense), net | (24,751) | (7,111,918) |
| Gain on debt extinguishment | — | 16,700 |
| Income before income taxes | (137,706) | (7,295,334) |
| Income tax expense/(benefit) | — | — |
| Net income | (137,706) | (7,295,334) |
Condensed Consolidated Balance Sheets (Unaudited)
| Description | June 30, 2026 | December 31, 2025 |
|---|---|---|
| ASSETS | ||
| Current Assets | ||
| Cash | 10,971 | 29,553 |
| Investment in equity securities, at fair value | 874,810 | 915,310 |
| Total Current Assets | 885,781 | 944,863 |
| Advances to related parties, net of allowance for bad debts | 1,850 | 1,250 |
| Property and equipment, net | 1,799 | 1,912 |
| Intangible assets, net | 2,805 | 3,271 |
| Goodwill | 1,275,811 | 1,275,811 |
| Total Assets | 2,168,046 | 2,227,107 |
| LIABILITIES AND STOCKHOLDERS' DEFICIT | ||
| Current Liabilities | ||
| Accounts payable and accrued expenses | 217,363 | 190,469 |
| Accrued interest related parties | 50,107 | 42,286 |
| Fair value of convertible component in convertible loans | 174,387 | 174,387 |
| Convertible notes payable | 183,270 | 183,270 |
| Notes payable to related parties | 278,833 | 249,683 |
| Total Current Liabilities | 903,960 | 840,095 |
| Long-term liabilities | ||
| Stock payable | 1,584,797 | 1,416,047 |
| Total Liabilities | 2,488,757 | 2,256,142 |
| Commitments and contingencies (Notes 6 and 8) | ||
| Stockholders' Deficit | ||
| Preferred Stock $0.001 par value; 5,000,000 shares authorized; 4,652,675 shares issued and outstanding, respectively | 4,653 | 4,653 |
| Common stock $0.001 par value; 495,000,000 shares authorized; 162,609,031 and 160,109,031 shares issued and outstanding, respectively | 162,608 | 160,108 |
| Additional paid-in capital | 82,381,934 | 82,337,934 |
| Warrant equity | 18,702 | 18,702 |
| Accumulated deficit | (84,714,880) | (84,389,964) |
| Total Dogecoin Cash Inc. Stockholders' Deficit | (2,146,983) | (1,868,567) |
| Non-Controlling Interest | 1,826,272 | 1,839,532 |
| Total Stockholders' Deficit | (320,711) | (29,035) |
| Total Liabilities and Stockholders' Deficit | 2,168,046 | 2,227,107 |
| The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. | ||
Condensed Consolidated Statements of Cash Flows (Unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash Flows From Operating Activities: | ||
| Net loss for the period | (338,176) | (7,402,698) |
| Adjustments to reconcile net loss for the period to net cash | ||
| used in operating activities: | ||
| Allowance for bad debt | - | 75,055 |
| Unrealized (gain) loss on investments | 40,500 | (450) |
| Impairment of goodwill | - | - |
| Impairment expense digital currency | - | 7,079,850 |
| Depreciation and amortization | 580 | 603 |
| Common stock issued for consulting services | 46,500 | - |
| Loss on debt settlement | - | 16,700 |
| Professional fee expense paid with note payable conversion | - | 1,458 |
| Stock payable for services | 168,750 | 168,750 |
| Note payable issued for services | 25,000 | 25,000 |
| Changes in Assets and Liabilities: | ||
| Accounts payable and accrued expenses | 26,893 | 35,288 |
| Fair value of convertible component in convertible loans | - | (103) |
| Accrued interest related parties | 7,821 | 5,755 |
| Net Cash Provided by (Used in) Operating Activities | (22,132) | 5,208 |
| Cash Flows from Investing Activities: | ||
| Advances to related party | (600) | - |
| Net Cash Used in Investing Activities | (600) | - |
| Cash Flows from Financing Activities: | ||
| Proceeds from related parties notes payable, net | 4,150 | 10,706 |
| Net Cash Provided by Financing Activities | 4,150 | 10,706 |
| NET CHANGE IN CASH | (18,582) | 15,914 |
| CASH AT BEGINNING OF PERIOD | 29,553 | 34,934 |
| CASH AT END OF PERIOD | 10,971 | 50,848 |
| Supplemental Disclosures of Non Cash Activities: | ||
| Noncash investing and financing activities | ||
| Preferred shares issued for divided payable included in stock payable | - | 2,741 |
| Preferred shares of subsidiary issued in acquisition of digital currency | - | 7,500,000 |
| Common shares issued in acquisition of digital currency | - | 4,200 |
| Shares issued in consideration of convertible notes payable | - | 28,947 |
| Common stock issued for services | 46,500 | 123,860 |
| The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. | ||
Amounts in USD as reported; EPS as reported. Statements found on the EDGAR/iXBRL face print as filed; the rest are presentation-friendly mappings of filer XBRL tags. Use EDGAR for interactive notes and detail. Interactive statements & notes on EDGAR ↗
About Dogecoin Cash, Inc.
Source: Item 1 (Business) from the 10-K filed March 27, 2026. Description as filed by the company with the SEC.
Item 1. Business
Overview
Dogecoin Cash, Inc. (the “Company”), formerly Cannabis Sativa, Inc. and previously Ultra Sun Corporation, was incorporated under the laws of the State of Nevada in November 2004.
The Company currently conducts its principal operations through its majority-owned subsidiary PrestoCorp, Inc., doing business as PrestoDoctor, which operates a telemedicine platform that connects patients with licensed physicians who conduct medical cannabis evaluations through secure video consultations in jurisdictions where such services are permitted under applicable state laws.
The Company provides the technology platform and administrative support that facilitate telemedicine consultations between patients and licensed physicians. The physicians who conduct medical cannabis evaluations through the PrestoDoctor platform are independent medical professionals who are responsible for the medical services they provide to patients in accordance with applicable state laws and professional standards.
The Company’s primary operating activity is the provision of telemedicine services through the PrestoDoctor platform. References to digital assets or related technology initiatives relate to exploratory or ancillary activities conducted through subsidiaries and do not represent the Company’s principal source of revenue.
The Company is not affiliated with, endorsed by, or otherwise associated with the cryptocurrency known as “Dogecoin” or any related digital asset project, and the Company does not issue or sponsor any cryptocurrency.
Read full description ↓
Business Model
The Company operates a technology-enabled telemedicine platform that facilitates medical cannabis evaluations conducted by licensed physicians where permitted by applicable state laws.
Patients schedule consultations through the PrestoDoctor platform and are connected with licensed physicians who conduct telemedicine consultations remotely using secure online technology.
The Company generates substantially all of its revenue from telemedicine consultation services facilitated through the PrestoDoctor platform.
Asset-Light Platform Model
The Company operates using an asset-light platform model in which telemedicine services are facilitated through digital infrastructure rather than through ownership of physical clinic locations or healthcare facilities.
The PrestoDoctor platform connects patients with licensed physicians through secure proprietary online technology, enabling telemedicine consultations to occur remotely in jurisdictions where permitted by applicable state laws.
2
Corporate Strategy
The Company’s strategy is to continue expanding its telemedicine platform while maintaining a capital-efficient operating structure.
The Company also maintains intellectual property assets and evaluates technology initiatives through subsidiaries including Dogecoin Treasury Inc., Dogespac LLC, and Meme Coins Inc.
Intellectual Property
The Company maintains cannabis-related intellectual property through Kubby Patent and Licenses, LLC.
This intellectual property includes:
• the Ecuadorian Sativa cannabis strain plant patent (CTA)
• a patent relating to a method of treating hypertension using a cannabinoid-containing lozenge delivery system.
While the Company maintains certain cannabis-related intellectual property assets, substantially all current revenues are generated from telemedicine consultation services facilitated through the PrestoDoctor platform.
Corporate Structure
The Company conducts its operations through a combination of operating and strategic subsidiaries.
Operating Subsidiary
• PrestoCorp, Inc. – telemedicine services conducted through the PrestoDoctor platform.
Strategic and Technology Subsidiaries
• Dogecoin Treasury, Inc. – technology initiative and digital asset treasury activities
• DogeSPAC LLC – digital asset acquisition entity
• Meme Coins, Inc. – digital asset investment subsidiary
Other Subsidiaries
• Kubby Patent and Licenses, LLC – intellectual property
• Eden Holdings LLC – trademark holdings
• Wild Earth Naturals, Inc. – inactive subsidiary
• Hi Brands International, Inc. – inactive subsidiary
Certain subsidiaries, including DogeSPAC LLC, Meme Coins, Inc., and Dogecoin Treasury, Inc., support the Company’s digital asset acquisition, investment, and treasury management initiatives.
Operating Segments
The Company currently operates primarily through a single reportable operating segment consisting of telemedicine services conducted through PrestoCorp, Inc.
3
Facilities
The Company maintains its principal executive office at:
355 West Mesquite Boulevard
Suite C70
Mesquite, Nevada 89027
The office space is utilized pursuant to a rental arrangement.
Many administrative functions of the Company are conducted remotely.
PrestoCorp, Inc. maintains office space in New York used for operational and administrative support.
The office space is utilized pursuant to a month-to-month rental arrangement.
Competition
The Company competes with other telemedicine platforms and healthcare technology providers offering remote consultation services.
Many competitors may have greater financial resources, larger physician networks, and more extensive technology infrastructure.
Government Regulation
Telemedicine services are subject to federal and state laws governing healthcare delivery, telemedicine practice, and patient privacy.
The physicians who conduct consultations through the PrestoDoctor platform are responsible for complying with applicable professional licensing and regulatory requirements.
Telemedicine services in the United States are subject to federal and state laws and regulations governing healthcare services, telemedicine practice, and the protection of patient information. These laws and regulations may include state licensing requirements applicable to physicians, telehealth practice standards, and privacy and data protection laws such as the Health Insurance Portability and Accountability Act (“HIPAA”). The Company’s telemedicine platform facilitates consultations between patients and licensed physicians and relies on third-party technology infrastructure and healthcare professionals operating in accordance with applicable state regulatory frameworks.
The physicians who conduct medical cannabis evaluations through the PrestoDoctor platform are independent medical professionals who are responsible for the medical services they provide to patients in accordance with applicable state laws and professional standards. The Company provides the technology platform and administrative support that facilitate these telemedicine consultations.
Although the Company holds certain cannabis-related intellectual property and may evaluate potential licensing opportunities in jurisdictions where cannabis activities are permitted under applicable state laws, the Company does not currently cultivate, distribute, or sell cannabis products.
Cannabis remains classified as a Schedule I controlled substance under the federal Controlled Substances Act (“CSA”). While a number of states have adopted laws permitting medical or adult-use cannabis
4
activities under state regulatory frameworks, such activities remain illegal under federal law. As a result, any future activities involving cannabis-related products or licensing arrangements could be subject to regulatory uncertainty and legal risks. The Company intends to comply with applicable federal, state, and local laws in jurisdictions in which it conducts business.
The Company’s current operations consist primarily of telemedicine services conducted through the PrestoDoctor platform and do not involve the cultivation, manufacture, or sale of cannabis products.